Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of definitive radiochemotherapy for locally advanced vulvar squamous cell carcinoma
2006-004052-20Phase 2Active
- Sponsor
- KWF Kankerbestrijding
- Start
- Sep 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in Vulval carcinoma and vulvar squamous cell carcinoma (VSCC), sponsored by KWF Kankerbestrijding. Primary endpoint: Locoregional control rate at 12 weeks. Started Sep 2006; status: active.
02
Drugs
capecitabine
03
Conditions
Vulval carcinomavulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on 2006-004052-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004052-20.